2025
Quinagolide vaginal ring for reduction of endometriotic lesions: Results from the QLARITY trial
Pellicer A, Taylor H, Alberich-Bayarri A, Liu Y, Gamborg M, Barletta K, Pinton P, Heiser P, Bagger Y. Quinagolide vaginal ring for reduction of endometriotic lesions: Results from the QLARITY trial. European Journal Of Obstetrics & Gynecology And Reproductive Biology 2025, 310: 113946. PMID: 40188683, DOI: 10.1016/j.ejogrb.2025.113946.Peer-Reviewed Original ResearchConceptsDeep infiltrating endometriosisVaginal ringNo significant differenceLesion sizeBleeding patternsMenstrual cycleSignificant differenceImaging biomarkersSerum prolactin levelsPhase 2 trialMenstrual bleeding patternsEndpoint of reductionPatient-reported outcomesHigh-resolution MRIInfiltrating endometriosisPlacebo groupDouble-blindPlacebo-ControlledAdvanced diseaseEndometriotic lesionsPrimary endpointPain reductionSecondary endpointsProlactin levelsAdverse eventsShort-term estradiol administration does not restore endothelin‐B receptor‐mediated vasodilation in postmenopausal women
Nuckols V, Shoemaker L, Kuczmarski A, Haigh K, McGinty S, Del Vecchio A, Schwab A, Edwards D, Taylor H, Wenner M. Short-term estradiol administration does not restore endothelin‐B receptor‐mediated vasodilation in postmenopausal women. AJP Heart And Circulatory Physiology 2025, 328: h327-h332. PMID: 39773019, PMCID: PMC12175985, DOI: 10.1152/ajpheart.00815.2024.Peer-Reviewed Original ResearchConceptsPostmenopausal womenExogenous estradiol administrationEndothelin B receptorEstradiol administrationPremenopausal womenLactated RingeHealthy postmenopausal womenYoung womenLaser Doppler flowmetryEndothelin-BVasodilatory responseTransdermal patchDoppler flowmetryCutaneous microcirculationVasodilationEstradiolAdministrationWomenReceptorsRingerBlockadeFlowmetry
2021
Miscarriage determination in first trimester based on alpha-fetoprotein extracted from sanitary pads
Mor A, Gardezi M, Jubanyik K, Simsek B, Seifer DB, Patrizio P, Esencan E, Imamoglu G, Zhang M, Nichols-Burns SM, Taylor HS. Miscarriage determination in first trimester based on alpha-fetoprotein extracted from sanitary pads. Fertility And Sterility 2021, 116: 462-469. PMID: 33461753, DOI: 10.1016/j.fertnstert.2020.10.006.Peer-Reviewed Original ResearchConceptsExtrauterine pregnancyVaginal bloodAlpha-fetoproteinOngoing pregnancyAFP levelsSanitary padsHigh alpha-fetoprotein levelsOngoing pregnancy groupProspective cohort studyAlpha-fetoprotein levelsAcademic medical centerPregnancy groupCohort studyMiscarriage casesFirst trimesterOffice visitsMedical CenterMAIN OUTCOMEPregnancyMedian levelsMiscarriageBloodAnxiety levelsAFPCharacteristic analysisEndometriosis stromal cells induce bone marrow mesenchymal stem cell differentiation and PD-1 expression through paracrine signaling
Chen P, Mamillapalli R, Habata S, Taylor HS. Endometriosis stromal cells induce bone marrow mesenchymal stem cell differentiation and PD-1 expression through paracrine signaling. Molecular And Cellular Biochemistry 2021, 476: 1717-1727. PMID: 33428059, DOI: 10.1007/s11010-020-04012-1.Peer-Reviewed Original ResearchConceptsPD-1 expressionPD-1Stromal cellsT-cell PD-1 expressionEndometriosis stromal cellsGrowth of endometriosisPD-1 inductionDifferentiation of BMDCsBone marrow mesenchymal stem cell differentiationT cell quiescenceBMDC differentiationImmune toleranceEndometriosis patientsEndometriotic lesionsNormal endometriumEndometrial cellsEndometriosis cellsGynecological disordersImmune surveillanceMurine modelBMDCsEndometriosisLesion sizeCXCR4 receptorLesions
2020
Responsiveness and thresholds for clinically meaningful changes in worst pain numerical rating scale for dysmenorrhea and nonmenstrual pelvic pain in women with moderate to severe endometriosis
Pokrzywinski RM, Soliman AM, Snabes MC, Chen J, Taylor HS, Coyne KS. Responsiveness and thresholds for clinically meaningful changes in worst pain numerical rating scale for dysmenorrhea and nonmenstrual pelvic pain in women with moderate to severe endometriosis. Fertility And Sterility 2020, 115: 423-430. PMID: 33066973, DOI: 10.1016/j.fertnstert.2020.07.013.Peer-Reviewed Original ResearchConceptsSevere endometriosis-associated painEndometriosis-associated painNumerical rating scaleNonmenstrual pelvic painPelvic painWorst painMonth 3Rating ScalePain numerical rating scaleMeaningful changePremenopausal womenSevere endometriosisGlobal ImpressionClinical trialsMAIN OUTCOMEPainDysmenorrheaPhase IIIWomenElagolixResponsivenessTrialsPlaceboEndometriosisPatientsLessons from KEEPS: the Kronos Early Estrogen Prevention Study
Miller VM, Taylor HS, Naftolin F, Manson JE, Gleason CE, Brinton EA, Kling JM, Cedars MI, Dowling NM, Kantarci K, Harman SM. Lessons from KEEPS: the Kronos Early Estrogen Prevention Study. Climacteric 2020, 24: 139-145. PMID: 32880220, PMCID: PMC8108428, DOI: 10.1080/13697137.2020.1804545.Peer-Reviewed Original ResearchConceptsKronos Early Estrogen Prevention StudyCarotid intima-medial thicknessPrevention StudyCardiovascular diseaseOral conjugated equine estrogenClinical CVD eventsUse of MHTOvert cardiovascular diseasePlacebo-controlled trialConjugated equine estrogensCoronary artery calciumIntima-medial thicknessMode of deliveryUptake of estrogensMood/anxietyAge-related increaseGenetic variantsCVD eventsAgatston unitsArtery calciumSymptom reliefPlacebo pillsEquine estrogensMenopausal womenMenopausal symptomsTreatment of endometriosis-associated pain with linzagolix, an oral gonadotropin-releasing hormone–antagonist: a randomized clinical trial
Donnez J, Taylor HS, Taylor RN, Akin MD, Tatarchuk TF, Wilk K, Gotteland JP, Lecomte V, Bestel E. Treatment of endometriosis-associated pain with linzagolix, an oral gonadotropin-releasing hormone–antagonist: a randomized clinical trial. Fertility And Sterility 2020, 114: 44-55. PMID: 32505383, DOI: 10.1016/j.fertnstert.2020.02.114.Peer-Reviewed Original ResearchConceptsEndometriosis-associated painBone mineral densityNon-menstrual pelvic painPelvic painDose-dependent fashionSerum estradiolOral gonadotropin-releasing hormone antagonistSevere endometriosis-associated painGonadotropin-releasing hormone antagonistOverall pelvic painRates of amenorrheaDose-ranging trialRandomized clinical trialsNumber of respondersPrimary endpointBMD lossTotal hipFemoral neckHormone antagonistClinical centersParallel groupClinical trialsMineral densityLife measuresMAIN OUTCOMEEstrogen receptor-α immunoreactivity predicts symptom severity and pain recurrence in deep endometriosis
Pluchino N, Mamillapalli R, Wenger JM, Ramyead L, Drakopoulos P, Tille JC, Taylor HS. Estrogen receptor-α immunoreactivity predicts symptom severity and pain recurrence in deep endometriosis. Fertility And Sterility 2020, 113: 1224-1231.e1. PMID: 32416979, DOI: 10.1016/j.fertnstert.2020.01.036.Peer-Reviewed Original ResearchMeSH KeywordsAdultBiomarkersConstipationCross-Sectional StudiesDysmenorrheaDyspareuniaEndometriosisEstrogen Receptor alphaFemaleHumansImmunohistochemistryMiddle AgedPain MeasurementPredictive Value of TestsProgestinsRecurrenceRisk AssessmentRisk FactorsSeverity of Illness IndexTissue Array AnalysisTreatment OutcomeYoung AdultConceptsER-α expressionNumerical rating scaleProgesterone receptorAndrogen receptorDeep dyspareuniaDeep endometriosisImmunoreactive scoreProgestin therapyReceptor expressionTissue microarrayExpression of PRMultivariate logistic regression analysisER-α levelsSteroid receptor expressionTime of surgerySeverity of dysmenorrheaSeverity of symptomsLogistic regression analysisNonmenstrual painPain recurrencePain symptomsSevere dysmenorrheaPain persistencePain severityProgestin treatmentAccurate diagnosis of endometriosis using serum microRNAs
Moustafa S, Burn M, Mamillapalli R, Nematian S, Flores V, Taylor HS. Accurate diagnosis of endometriosis using serum microRNAs. American Journal Of Obstetrics And Gynecology 2020, 223: 557.e1-557.e11. PMID: 32165186, DOI: 10.1016/j.ajog.2020.02.050.Peer-Reviewed Original ResearchConceptsStage I/IIAbsence of endometriosisMiR-150-5pSerum microRNAsDisease progressionControl groupMiR-451aStage III/IVExpression levelsMiR-125bReproductive Medicine stagingTimely disease detectionTime of surgeryReceiver-operating characteristic areaPresence of symptomsReceiver-operating characteristic analysisNoninvasive diagnostic testMicroRNA biomarkersAcademic medical centerReal-time polymerase chain reactionControl group subjectsHealth care costsQuantitative real-time polymerase chain reactionYears of discomfortNoninvasive diagnostic methodCXCL12 Attracts Bone Marrow-Derived Cells to Uterine Leiomyomas
Moridi I, Mamillapalli R, Kodaman PH, Habata S, Dang T, Taylor HS. CXCL12 Attracts Bone Marrow-Derived Cells to Uterine Leiomyomas. Reproductive Sciences 2020, 27: 1724-1730. PMID: 32020550, DOI: 10.1007/s43032-020-00166-x.Peer-Reviewed Original ResearchConceptsBone marrow-derived cellsMarrow-derived cellsExpression of CXCL12Uterine leiomyomaLeiomyoma growthCommon benign gynecologic tumorsNormal myometriumEngraftment of BMDCsBenign gynecologic tumorsCXCR4 antagonist AMD3100Myometrium of womenStem/progenitor cellsUterine myomaGynecologic tumorsMyoma cellsAntagonist AMD3100CXCR4 expressionControl myometriumReproductive ageUterine diseaseMouse uterusCurrent evidenceLeiomyomaBone marrowMyometriumHeart fat and carotid artery atherosclerosis progression in recently menopausal women: impact of menopausal hormone therapy: The KEEPS trial.
El Khoudary SR, Venugopal V, Manson JE, Brooks MM, Santoro N, Black DM, Harman M, Naftolin F, Hodis H, Brinton E, Miller V, Taylor H, Budoff M. Heart fat and carotid artery atherosclerosis progression in recently menopausal women: impact of menopausal hormone therapy: The KEEPS trial. Menopause The Journal Of The North American Menopause Society 2020, 27: 255-262. PMID: 32015261, PMCID: PMC7113029, DOI: 10.1097/gme.0000000000001472.Peer-Reviewed Original ResearchConceptsCarotid intima-media thicknessEpicardial adipose tissueProgression of atherosclerosisCIMT progressionHormone therapyAtherosclerosis progressionMenopausal womenOral conjugated equine estrogenParacardial adipose tissue volumeMenopausal hormone therapyPlacebo-controlled trialConjugated equine estrogensFat depositionIntima-media thicknessMcg/dAdipose tissue volumeRoute of administrationPAT changesCEE administrationPlacebo groupEquine estrogensT-E2Fat accumulationMonth progressionO-CEE
2019
Achieving clinically meaningful response in endometriosis pain symptoms is associated with improvements in health-related quality of life and work productivity: analysis of 2 phase III clinical trials
Pokrzywinski RM, Soliman AM, Chen J, Snabes MC, Coyne KS, Surrey ES, Taylor HS. Achieving clinically meaningful response in endometriosis pain symptoms is associated with improvements in health-related quality of life and work productivity: analysis of 2 phase III clinical trials. American Journal Of Obstetrics And Gynecology 2019, 222: 592.e1-592.e10. PMID: 31759891, DOI: 10.1016/j.ajog.2019.11.1255.Peer-Reviewed Original ResearchConceptsEndometriosis Health Profile-30Nonmenstrual pelvic painHealth-related qualityEndometriosis-associated painPelvic painMonth 3Clinical responseClinical respondersPain symptomsMeaningful improvementsEndometriosis-related pain symptomsSevere endometriosis-associated painSevere endometriosis-related painGonadotropin-releasing hormone antagonistPhase III clinical trialsPain reduction scoresPain responder statusSelf-reported bleedingPlacebo-controlled studyEndometriosis-related painSelf-reported painWork productivityReceiver-operating characteristic analysisNumber of symptomsProductivity QuestionnaireImpact of menopausal hormone formulations on pituitary-ovarian regulatory feedback
Kling JM, Dowling NM, Bimonte-Nelson HA, Gleason CE, Kantarci K, Manson JE, Taylor HS, Brinton EA, Lobo RA, Cedars MI, Pal L, Neal-Perry G, Naftolin F, Harman SM, Miller VM. Impact of menopausal hormone formulations on pituitary-ovarian regulatory feedback. AJP Regulatory Integrative And Comparative Physiology 2019, 317: r912-r920. PMID: 31663769, PMCID: PMC6957372, DOI: 10.1152/ajpregu.00234.2019.Peer-Reviewed Original ResearchConceptsFollicle-stimulating hormoneKronos Early Estrogen Prevention StudyHormone levelsHormone therapyT-E2Menopausal womenTreatment groupsOral conjugated equine estrogenCommon hormone therapiesPituitary-ovarian hormonesPostmenopausal hormone therapyActive treatment groupConjugated equine estrogensMo of treatmentDouble-blinded treatmentPlacebo groupEquine estrogensMenopausal transitionPrevention StudyO-CEEHormonal modulationBaseline levelsCognitive declinePlaceboHormone formulationsEffects of Hormone Therapy on Heart Fat and Coronary Artery Calcification Progression: Secondary Analysis From the KEEPS Trial
Khoudary S, Zhao Q, Venugopal V, Manson JE, Brooks MM, Santoro N, Black DM, Harman SM, Cedars MI, Hopkins PN, Kearns AE, Miller VM, Taylor HS, Budoff MJ. Effects of Hormone Therapy on Heart Fat and Coronary Artery Calcification Progression: Secondary Analysis From the KEEPS Trial. Journal Of The American Heart Association 2019, 8: e012763. PMID: 31652073, PMCID: PMC6761637, DOI: 10.1161/jaha.119.012763.Peer-Reviewed Original ResearchConceptsOral conjugated equine estrogenConjugated equine estrogensCoronary artery calcification (CAC) progressionBaseline CAC scoreEpicardial adipose tissueCAC scoreEquine estrogensMenopausal womenCAC progressionCalcification progressionAdipose tissueEpicardial adipose tissue accumulationEarly menopausal womenPlacebo-controlled trialAdipose tissue accumulationHormone therapy formulationsProgression of CACKEEP participantsHormone therapySubclinical atherosclerosisCAC measuresEndogenous estrogensFat accumulationTreatment groupsFat depotsPatterns of Prescription Opioid Use in Women With Endometriosis
Lamvu G, Soliman AM, Manthena SR, Gordon K, Knight J, Taylor HS. Patterns of Prescription Opioid Use in Women With Endometriosis. Obstetrics And Gynecology 2019, 133: 1120-1130. PMID: 31135725, PMCID: PMC6553518, DOI: 10.1097/aog.0000000000003267.Peer-Reviewed Original ResearchConceptsOpioid prescriptionsControl groupBenzodiazepine prescriptionsOpioid useEndometriosis patientsCase groupClinformatics DataMart databaseFirst opioid prescriptionMultiple opioid prescriptionsOpioid Prescribing PatternsPrescription opioid useMultivariable regression analysisRelative risk ratiosConcomitant opioidsPrescribing patternsDaily doseMean ageRisk ratioConcomitant useDays' supplyRetrospective analysisInsurance payerΧ statisticEndometriosisPatientsThe Kronos Early Estrogen Prevention Study (KEEPS): what have we learned?
Miller VM, Naftolin F, Asthana S, Black DM, Brinton EA, Budoff MJ, Cedars MI, Dowling NM, Gleason CE, Hodis HN, Jayachandran M, Kantarci K, Lobo RA, Manson JE, Pal L, Santoro NF, Taylor HS, Harman SM. The Kronos Early Estrogen Prevention Study (KEEPS): what have we learned? Menopause The Journal Of The North American Menopause Society 2019, 26: 1071-1084. PMID: 31453973, PMCID: PMC6738629, DOI: 10.1097/gme.0000000000001326.Peer-Reviewed Original ResearchConceptsKronos Early Estrogen Prevention StudyCarotid artery intima-media thicknessPostmenopausal womenPrevention StudyAncillary studiesO-CEEHealth initiativesArtery intima-media thicknessInitiation of HTPlacebo-controlled trialCoronary artery calciumEffect of menopauseWomen's Health InitiativeIntima-media thicknessProgression of atherosclerosisAge of menopauseBone mineral densitySevere adverse effectsWhite matter hyperintensitiesVariants of genesMenopausal hormonesBreast painArtery calciumUse of HTVenous thrombosisNerve Growth Factor Improves the Outcome of Type 2 Diabetes—Induced Hypotestosteronemia and Erectile Dysfunction
Wu Y, Yang C, Meng F, Que F, Xiao W, Rao H, Wan Y, Taylor HS, Lu L. Nerve Growth Factor Improves the Outcome of Type 2 Diabetes—Induced Hypotestosteronemia and Erectile Dysfunction. Reproductive Sciences 2019, 26: 386-393. PMID: 29724155, DOI: 10.1177/1933719118773421.Peer-Reviewed Original ResearchConceptsNerve growth factorErectile dysfunctionTotal testosteroneFree testosteroneDiabetes-induced erectile dysfunctionNGF treatmentGrowth factorHyperglycemia-induced downregulationErectile Function scoreIIEF-5 scoreSerum total testosteroneType 2 diabetesMouse Leydig cellsSteroidogenic acute regulatory proteinDiabetic malesSensorimotor polyneuropathySerum testosteroneFunction scoresAcute regulatory proteinInternational IndexClinical studiesED outcomesCytochrome P450 11A1Testosterone biosynthesisLeydig cells
2018
Development of the Painful Periods Screening Tool for endometriosis
DiBenedetti DB, Soliman AM, Ervin C, Evans E, Coddington CC, Agarwal SK, Surrey ES, Taylor HS. Development of the Painful Periods Screening Tool for endometriosis. Postgraduate Medicine 2018, 130: 694-702. PMID: 30334456, DOI: 10.1080/00325481.2018.1526623.Peer-Reviewed Original ResearchConceptsEndometriosis symptomsHealthy controlsScreening toolEndometriosis-related symptomsTreatment of endometriosisCross-sectional qualitative studyDiagnostic delayEarly diagnosisEndometriosisUnmet needCore symptomsSymptomsClinical expertsDraft itemsWomenPatientsDepth individual interviewsPhysiciansQualitative studyIndividual interviewsRounds of interviewsDiagnosisLong-Term Outcomes of Elagolix in Women With Endometriosis
Surrey E, Taylor HS, Giudice L, Lessey BA, Abrao MS, Archer DF, Diamond MP, Johnson NP, Watts NB, Gallagher JC, Simon JA, Carr BR, Dmowski WP, Leyland N, Singh SS, Rechberger T, Agarwal SK, Duan WR, Schwefel B, Thomas JW, Peloso PM, Ng J, Soliman AM, Chwalisz K. Long-Term Outcomes of Elagolix in Women With Endometriosis. Obstetrics And Gynecology 2018, 132: 147-160. PMID: 29889764, DOI: 10.1097/aog.0000000000002675.Peer-Reviewed Original ResearchConceptsMonths of treatmentResponder rateAdverse eventsPlacebo-controlled phase 3 trialGonadotropin-releasing hormone antagonistBone mineral density assessmentCoprimary efficacy endpointsEndometriosis-associated painNonmenstrual pelvic painPelvic pain scoresSafety of elagolixCommon adverse eventsPhase 3 trialProportion of respondersNew safety concernsBone mineral densityClinical laboratory testsElagolix dosesElagolix treatmentEndometrial findingsEfficacy endpointPain scoresPelvic painHot flushesTerm outcomesHematogenous Dissemination of Mesenchymal Stem Cells from Endometriosis
Li F, Alderman MH, Tal A, Mamillapalli R, Coolidge A, Hufnagel D, Wang Z, Neisani E, Gidicsin S, Krikun G, Taylor HS. Hematogenous Dissemination of Mesenchymal Stem Cells from Endometriosis. Stem Cells 2018, 36: 881-890. PMID: 29450941, PMCID: PMC5992028, DOI: 10.1002/stem.2804.Peer-Reviewed Original ResearchConceptsSerum CXCL12 levelsCXCL12 levelsEndometrial tissueEndometriosis lesionsHematogenous disseminationMesenchymal stem cell biomarkersCXCL12/CXCR4 axisStem cellsTreatment of endometriosisSham control miceEndometrial stem cellsHematopoietic stem cell markersStem cell biomarkersStem cell markersSpontaneous endometriosisRetrograde menstruationControl miceExperimental endometriosisRecipient miceCXCR4 axisLung tissueEndometriosisPeritoneal cavityDsRed miceBlood of animals
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply